Skip to content
DraconiticResearch
Search Sources API
201,642 studies31 sourcesUpdated 14 min ago
Peer-reviewedCC BY-NC 4.0BMJ Open

High-density lipoprotein (HDL) dysfunctionality in autoimmune connective tissue diseases: protocol for a systematic review

  • Yasuhiro Endo1
  • Kei Sasaki2
  • Masatsune Ogura3
  1. 1Faculty of Medical Technology, Niigata University of Pharmacy, Niigata, Japan
  2. 2Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
  3. 3Department of Clinical Laboratory Technology, Juntendo University, Tokyo, Japan
Read full textDOICite

Abstract

Introduction: Autoimmune connective tissue diseases (AICTDs) are associated with both chronic inflammation and an increased risk of atherosclerotic cardiovascular disease beyond that conferred by traditional risk factors. High-density lipoprotein (HDL) exerts anti-atherogenic effects through its cholesterol efflux capacity (CEC), which inflammation may impair. Although HDL dysfunction has been reported in AICTDs, the role of this dysfunction in connective tissue diseases has not yet been systematically evaluated.

Methods and analysis: The study protocol was registered in the International Prospective Register of Systematic Reviews (CRD420251183500). From inception, the Medical Literature Analysis and Retrieval System Online, Excerpta Medica database and the Cochrane Central Register of Controlled Trials will be searched. The review is scheduled to run from October 2026 to August 2027. Observational and interventional studies in adults with AICTDs reporting quantitative measures of HDL functionality, including CEC, antioxidant capacity, anti-inflammatory function and endothelial protective function, will be included. The study will be independently conducted by two reviewers.

Ethics and dissemination: Because this study will be a systematic review based on previously published data and will not involve individual patient data, ethical approval is not required. The findings will be disseminated through publication in a peer-reviewed journal and will be presented at a conference.

PROSPERO registration number: CRD420251183500.

Related

  1. Dermatoscopic Assessment of Nail Fold Capillary Patterns in Patients of Color with Different Autoimmune Connective Tissue Diseases.
    Eman Ayesha, Sumera Hanif, Madeline Tchack +9
    Dermatology practical & conceptualPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  2. Endocrine–Immune Crosstalk in Pediatric Autoimmune Diseases: A Systematic Review of the Role of Micronutrients, with Emphasis on Vitamin D
    Atapattu Navoda, Sunil J. Wimalawansa
    NutrientsPeer-reviewedCC BYFull textNutritionEurope PMC
  3. Accuracy of diagnostic codes and algorithms used to identify connective tissue diseases in electronic health records and administrative databases: systematic review and meta-analysis.
    C. Saka-Herran, T. Mani Prabu Kumar, D. Keane +8
    medRxivPreprintCC BYFull textGeneral medicinemedRxiv
  4. Efficacy of nutraceuticals as adjunctive therapies in autoimmune diseases: A systematic review of clinical trials.
    Jennifer Carolina Flores Iglesias, Luis Fernando Méndez López
    BioImpacts : BIPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  5. Respiratory syncytial virus vaccination in systemic autoimmune rheumatic diseases: a systematic review
    Victoria Allen, Maryam Adas, Liyang Pan +4
    Rheumatology (Oxford, England)Peer-reviewedCC BY 4.0Full textEpidemiology & public healthPMC

Cite

BibTeXRIS
BibTeX
@article{endo2026highdensity,
  title = {{High-density lipoprotein (HDL) dysfunctionality in autoimmune connective tissue diseases: protocol for a systematic review}},
  author = {Yasuhiro Endo and Kei Sasaki and Masatsune Ogura},
  journal = {BMJ Open},
  year = {2026},
  month = oct,
  doi = {10.1136/bmjopen-2026-122567},
  url = {https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-122567},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - High-density lipoprotein (HDL) dysfunctionality in autoimmune connective tissue diseases: protocol for a systematic review
AU  - Yasuhiro Endo
AU  - Kei Sasaki
AU  - Masatsune Ogura
PY  - 2026
DA  - 2026/10/29
JO  - BMJ Open
DO  - 10.1136/bmjopen-2026-122567
UR  - https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-122567
AB  - Introduction: Autoimmune connective tissue diseases (AICTDs) are associated with both chronic inflammation and an increased risk of atherosclerotic cardiovascular disease beyond that conferred by traditional risk factors. High-density lipoprotein (HDL) exerts anti-atherogenic effects through its cholesterol efflux capacity (CEC), which inflammation may impair. Although HDL dysfunction has been reported in AICTDs, the role of this dysfunction in connective tissue diseases has not yet been systematically evaluated.  Methods and analysis: The study protocol was registered in the International Prospective Register of Systematic Reviews (CRD420251183500). From inception, the Medical Literature Analysis and Retrieval System Online, Excerpta Medica database and the Cochrane Central Register of Controlled Trials will be searched. The review is scheduled to run from October 2026 to August 2027. Observational and interventional studies in adults with AICTDs reporting quantitative measures of HDL functionality, including CEC, antioxidant capacity, anti-inflammatory function and endothelial protective function, will be included. The study will be independently conducted by two reviewers.  Ethics and dissemination: Because this study will be a systematic review based on previously published data and will not involve individual patient data, ethical approval is not required. The findings will be disseminated through publication in a peer-reviewed journal and will be presented at a conference.  PROSPERO registration number: CRD420251183500.
SN  - 2044-6055
SN  - 2044-6055
ER  -